Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality

Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality
Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a study. While patients reported a decline in these quality of life measures immediately after brachytherapy, they achieved a full recovery within six months. Brachytherapy involves inserting radioactive seeds in or near tumor to kill it. The research, "Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131," was published in the Journal of Radiation Oncology, Biology, Physics. "This study reinforces the position of Cesium 131 as an effective, patient-friendly treatment for localized prostate cancer," Bill Cavanagh, chief scientific officer of the brachytherapy company IsoRay, said in a news release. "This is especially important as multiple studies are emerging that strongly suggest that the inclusion of brachytherapy must be considered for the treatment of high-risk prostate cancer – the toughest localized prostate cancer to cure." Prostate brachytherapy alone, or combined with external beam radiation therapy (EBRT), is a widely used treatment for men with prostate cancer. By placing radioactive seeds in or near the tumor, brachytherapy spares surrounding, health
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *